Drugs / ERAS-0015
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06983743 | Jun 2025 → May 2028 expected | metastatic neoplasm | Erasca, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ERAS-0015 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06983743 ↗ |
| Route | Oral | “ERAS-0015 Administered orally” NCT06983743 ↗ |